New hope for lung cancer patients with brain tumors: triple therapy trial begins

NCT ID NCT06822543

First seen Oct 31, 2025 · Last updated May 08, 2026 · Updated 27 times

Summary

This study tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) in people with non-small cell lung cancer that has spread to the brain and has not been treated yet. The goal is to see if the treatment shrinks brain tumors. About 46 adults will receive the drugs every three weeks for four cycles, then continue with two of them until the disease worsens or side effects become too severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • FUNFARME - Hospital de Base de São José do Rio Preto

    RECRUITING

    São José do Rio Preto, São Paulo, 15.090-000, Brazil

    Contact

Conditions

Explore the condition pages connected to this study.